AMLX - Amylyx Pharmaceuticals, Inc.
IEX Last Trade
4.035
0.015 0.372%
Share volume: 2,153
Last Updated: Thu 26 Dec 2024 04:30:33 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$4.02
0.02
0.37%
Fundamental analysis
25%
Profitability
17%
Dept financing
5%
Liquidity
75%
Performance
25%
Performance
5 Days
-1.23%
1 Month
-29.33%
3 Months
28.21%
6 Months
116.22%
1 Year
-72.41%
2 Year
-88.75%
Key data
Stock price
$4.04
DAY RANGE
$3.98 - $4.05
52 WEEK RANGE
$1.66 - $19.95
52 WEEK CHANGE
-$72.49
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Joshua B. Cohen
Region: US
Website: amylyx.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amylyx.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.
Recent news